Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Cash from Operations (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Cash from Operations for 4 consecutive years, with 2270000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations rose 83.23% to 2270000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 48963000.0 through Dec 2025, up 3.15% year-over-year, with the annual reading at 48963000.0 for FY2025, 3.15% up from the prior year.
  • Cash from Operations for Q4 2025 was 2270000.0 at Orchestra BioMed Holdings, up from 14550000.0 in the prior quarter.
  • The five-year high for Cash from Operations was 2270000.0 in Q4 2025, with the low at 16616000.0 in Q1 2025.
  • Average Cash from Operations over 4 years is 10933562.5, with a median of 10732000.0 recorded in 2023.
  • The sharpest move saw Cash from Operations crashed 170.12% in 2023, then skyrocketed 83.23% in 2025.
  • Over 4 years, Cash from Operations stood at 8744000.0 in 2022, then dropped by 25.5% to 10974000.0 in 2023, then dropped by 23.36% to 13538000.0 in 2024, then surged by 83.23% to 2270000.0 in 2025.
  • According to Business Quant data, Cash from Operations over the past three periods came in at 2270000.0, 14550000.0, and 15527000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.